title: Expression of CD164 on Malignant T cells in Sézary Syndrome.
abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by pruritic erythroderma, peripheral lymphadenopathy and the presence of malignant T cells in the blood. Unequivocal detection of malignant cells in patients with Sézary syndrome is of important diagnostic, prognostic and therapeutic value. However, no single Sézary syndrome specific cell surface marker has been identified. In a cohort of patients with Sézary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls. CD164 expression was in most cases limited to CD4+CD26- malignant T lymphocytes, unequivocally identified using flow-cytometry by the expression of a specific Vβ clone for each patient. Increased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sézary syndrome.
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Gloriastr. 31, 8091 Zürich, Switzerland. Emmanuella.Guenova@usz.ch.
authors.forename: Emmanuella
authors.initials: E
authors.lastname: Guenova
authors.forename: Desislava
authors.initials: D
authors.lastname: Ignatova
authors.forename: Yun-Tsan
authors.initials: YT
authors.lastname: Chang
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Contassot
authors.forename: Tarun
authors.initials: T
authors.lastname: Mehra
authors.forename: Ieva
authors.initials: I
authors.lastname: Saulite
authors.forename: Alexander A
authors.initials: AA
authors.lastname: Navarini
authors.forename: Vanyo
authors.initials: V
authors.lastname: Mitev
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.forename: Dmitry V
authors.initials: DV
authors.lastname: Kazakov
authors.forename: Lars E
authors.initials: LE
authors.lastname: French
authors.forename: Wolfram
authors.initials: W
authors.lastname: Hoetzenecker
authors.forename: Antonio
authors.initials: A
authors.lastname: Cozzio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D016022:Case-Control Studies; D002478:Cells, Cultured; D018819:Dipeptidyl Peptidase 4 / Q000097:blood; D051930:Endolyn / Q000097:blood; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012751:Sezary Syndrome / Q000097:blood* / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D012878:Skin Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C497898:CD164 protein, human; D051930:Endolyn; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4